VESIcare LS Approved for Neurogenic Detrusor Overactivity
WEDNESDAY, May 27, 2020 -- VESIcare LS (solifenacin succinate) oral suspension is now approved to treat neurogenic detrusor overactivity (NDO) in children 2 years and older, the U.S. Food and Drug Administration announced Tuesday.
VESIcare...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
More News: Brain | Children | Food and Drug Administration (FDA) | General Medicine | Neurology | VESIcare